M&A · Healthcare · Pharmaceutical Preparations
Concentra Biosciences, LLC to acquire Allakos Inc.
Announced Apr 2, 2025 · Closed May 15, 2025
Deal value$30MEV $12M
Premium50.0%To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash$0.33 per share
Transaction
- Acquirer
- Concentra Biosciences, LLC
- Target
- Allakos Inc. (ALLK)
- Buyer type
- Private equity
- Offer price per share
- $0.33
- Enterprise value
- $12M
- Status
- Closed May 15, 2025
Deal protections
- Break fee (target pays)
- $1.2M · 4.0%
- Reverse fee (buyer pays)
- —
- Go-shop
- —
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- Houlihan Lokey
Sector context · Healthcare
- Comparable deals
- 93 in the prior 24 months
- Premium
- 50.0% vs. 65.5% sector median
- EV / Adj. EBITDA
- Sector median 13.8x
- Break fee
- 4.0% vs. 3.4% sector median
Timeline
- AnnouncedApr 2, 2025
- Tender offerApr 15, 2025
- ClosedMay 15, 2025
Valuation · fairness opinions
Liquidation$0.22$0.27
Offer $0.33
Implied value per Allakos Inc. share by analysis, from Houlihan Lokey.